Cell kinetics of human transitional cell carcinoma of the bladder by in vitro bromodeoxyuridine labeling / 대한비뇨기과학회지

ABSTRACT

We labeled S-phase cell in human bladder tumors using anti-bromodeoxyuridine (BrdU) antibody. The thymidine analogue, BrdU, was incorporated into DNA synthesis phase by in vitro labeling technique. Separate samples of 27 transitional cell bladder cancers were labeled, fixed with 7O per cent ethanol, embedded in paraffin, sectioned and stained by an immunoperoxidase method with anti-bromodeoxyuridine monoclonal antibody as the first antibody. The bromodeoxyuridine labeling index (LI), S phase fraction, was determined by counting the number of bromodeoxyuridine labeled cells in the tissue sections. The average LI in normal and bladder tumors were 2.99% and 11.8% respectively. All grade I and grade II tumors had a LI lower than 10%. while the average LI in grade III tumors was 2l.46%. The average LI for noninvasive (Ta and T1) and invasive tumors were 7.75 % and 26% respectively. The average LI in recurrent tumors were 15.37% compared to 7.76% in initial tumors. The high labeling index in tumors tissue appears to indicate a more malignant potential and thus a poor prognosis. Although further studies are required for its full significance, the measurement of BrdU labeling index by in vitro method may be a quantitative assay of biological potential of individual tumors and has practical value in the management of transitional cell carcinoma of the bladder.